Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma

Takaaki Nakashima, Takeshi Nonoshita, Hidenari Hirata, Kouji Inoue, Akira Nagashima, Tadamasa Yoshitake, Kaori Asai, Yoshiyuki Shioyama

Research output: Contribution to journalArticle

Abstract

Background: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. Patients and Methods: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. Results: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. Conclusion: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.

Original languageEnglish
Pages (from-to)247-253
Number of pages7
JournalIn Vivo
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 1 2020

Fingerprint

Radiotherapy
Brain
Neoplasm Metastasis
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Otitis Media
Ear
Toxicity
Adenocarcinoma of lung
Cells
Mutation
anaplastic lymphoma kinase

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma. / Nakashima, Takaaki; Nonoshita, Takeshi; Hirata, Hidenari; Inoue, Kouji; Nagashima, Akira; Yoshitake, Tadamasa; Asai, Kaori; Shioyama, Yoshiyuki.

In: In Vivo, Vol. 34, No. 1, 01.01.2020, p. 247-253.

Research output: Contribution to journalArticle

Nakashima, Takaaki ; Nonoshita, Takeshi ; Hirata, Hidenari ; Inoue, Kouji ; Nagashima, Akira ; Yoshitake, Tadamasa ; Asai, Kaori ; Shioyama, Yoshiyuki. / Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma. In: In Vivo. 2020 ; Vol. 34, No. 1. pp. 247-253.
@article{3e80840cb66f4ccdb90e329c786f66a8,
title = "Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma",
abstract = "Background: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. Patients and Methods: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. Results: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. Conclusion: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.",
author = "Takaaki Nakashima and Takeshi Nonoshita and Hidenari Hirata and Kouji Inoue and Akira Nagashima and Tadamasa Yoshitake and Kaori Asai and Yoshiyuki Shioyama",
year = "2020",
month = "1",
day = "1",
doi = "10.21873/invivo.11767",
language = "English",
volume = "34",
pages = "247--253",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma

AU - Nakashima, Takaaki

AU - Nonoshita, Takeshi

AU - Hirata, Hidenari

AU - Inoue, Kouji

AU - Nagashima, Akira

AU - Yoshitake, Tadamasa

AU - Asai, Kaori

AU - Shioyama, Yoshiyuki

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Background: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. Patients and Methods: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. Results: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. Conclusion: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.

AB - Background: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. Patients and Methods: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. Results: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. Conclusion: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85077252304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077252304&partnerID=8YFLogxK

U2 - 10.21873/invivo.11767

DO - 10.21873/invivo.11767

M3 - Article

C2 - 31882485

AN - SCOPUS:85077252304

VL - 34

SP - 247

EP - 253

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 1

ER -